This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 28 for:    "Pneumonia, Aspiration"
Previous Study | Return to List | Next Study

BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

This study has been completed.
Information provided by:
Bayer Identifier:
First received: January 8, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted
The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.

Condition Intervention Phase
Pneumonia, Aspiration Lung Abscess Drug: Avelox (Moxifloxacin, BAY12-8039) Drug: Sulbactam/Ampicillin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Multi-center, Randomized, Non-blind Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Sulbactam/Ampicillin in the Treatment of Pulmonary Abscess and Aspiration Pneumonia

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Adverse events occuring after first application of study medication up to the test of cure visit for non-serious adverse events [ Time Frame: Up to 30 days after end of treatment with study medication for serious adverse events ]

Secondary Outcome Measures:
  • Clinical Response [ Time Frame: Regulary doing i.v. treatment ]

Enrollment: 139
Study Start Date: February 2001
Study Completion Date: January 2005
Arms Assigned Interventions
Experimental: Arm 1 Drug: Avelox (Moxifloxacin, BAY12-8039)
Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
Active Comparator: Arm 2 Drug: Sulbactam/Ampicillin
Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients aged 18 years or above
  • The primary diagnosis is community or hospital acquired primary pulmonary abscess or aspiration pneumonia, requiring initial parenteral treatment

Exclusion Criteria:

  • Known hypersensitivity to fluoroquinolones and/or ß-lactams
  • Patients with mechanical ventilation lasting more than 48 hours prior to enrollment, with poststenotic pneumonia, infarction pneumonia, pulmonary tuberculosis, lung abscess/pneumonia with concomitant endocarditis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01045902

Mannheim, Baden-Württemberg, Germany, 68167
Nürnberg, Bayern, Germany, 90419
Regensburg, Bayern, Germany, 93053
Treuenbrietzen, Brandenburg, Germany, 14929
Frankfurt, Hessen, Germany, 60596
Hildesheim, Niedersachsen, Germany, 31134
Rotenburg, Niedersachsen, Germany, 27356
Lüdenscheid, Nordrhein-Westfalen, Germany, 58515
Oberhausen, Nordrhein-Westfalen, Germany, 46045
Paderborn, Nordrhein-Westfalen, Germany, 33098
Magdeburg, Sachsen-Anhalt, Germany, 39112
Leipzig, Sachsen, Germany, 04129
Lübeck, Schleswig-Holstein, Germany, 23538
Berlin, Germany, 13353
Berlin, Germany, 14165
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Therapeutic Area Head, Bayer HealthCare AG Identifier: NCT01045902     History of Changes
Other Study ID Numbers: 10381
Study First Received: January 8, 2010
Last Updated: January 8, 2010

Keywords provided by Bayer:
Pulmonary Abscess
Aspiration Pneumonia

Additional relevant MeSH terms:
Pneumonia, Aspiration
Lung Abscess
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Pathologic Processes
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors processed this record on August 23, 2017